Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

被引：4
|
作者：
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja C.
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
Miguel, Jesus San
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Mekan, Sabeen
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8028
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Kaufman, Jonathan
    Mazumder, Amitabha
    Moreau, Philippe
    Leleu, Xavier
    Fry, John
    Singhal, Anil
    Jagannath, Sundar
    BLOOD, 2009, 114 (22) : 179 - 180
  • [42] ELOQUENT-3 study: elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma - final analysis of overall survival (OS)
    Raab, M. S.
    Dimopoulos, M.
    Dytfeld, D.
    Grosicki, S.
    Moreau, P.
    Takezako, N.
    Hori, M.
    Leleu, X.
    LeBlanc, R.
    Suzuki, K.
    Richardson, P. G.
    Popa McKiver, M.
    Jou, Y. -M.
    Yao, D.
    Das, P.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 87 - 87
  • [43] ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).
    Lonial, Sagar
    Richardson, Paul Gerard Guy
    Moreau, Philippe
    Orlowski, Robert Z.
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Palumbo, Antonio Pierangelo
    Facon, Thierry
    Vij, Ravi
    White, Darrell
    Reece, Donna Ellen
    Singhal, Anil
    Kroog, Glenn Scott
    Kopit, Justin
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study
    Weisel, Katja
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Cocks, Kim
    Espensen, Ashlee
    Popa-McKiver, Mihaela
    Chen, Clara
    Cavo, Michele
    BLOOD, 2018, 132
  • [45] Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
    Minarik, Jiri
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pika, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Harvanova, Lubica
    Pospisilova, Lenka
    Krhovska, Petra
    Novakova, Denisa
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Maisnar, Vladimir
    Hajek, Roman
    CANCERS, 2022, 14 (20)
  • [46] Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 568 - +
  • [47] Final results for the 1703 phase 1b/2 study of Elotuzumab (Elo) in combination with Lenalidomide (Len) and dexamethasone (dex) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raab, M. S.
    Richardson, P. G.
    Jagannath, S.
    Moreau, P.
    Jakubowiak, A. J.
    Facon, T.
    Vij, R.
    White, D.
    Reece, D. E.
    Benboubker, L.
    Zonder, J.
    Tsao, L. C.
    Anderson, K. C.
    Bleickardt, E.
    Singhal, A. K.
    Lonial, S.
    Oncology Research and Treatment, 2015, 38 : 165 - 165
  • [48] Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Jagannath, Sundar
    Moreau, Philippe
    Jakubowiak, Andrzej
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    White, Darrell
    Reece, Donna E.
    Benboubker, Lotfi
    Zonder, Jeffrey
    Tsao, L. Claire
    Anderson, Kenneth C.
    Bleickardt, Eric
    Singhal, Anil K.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
  • [49] Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study
    Weisel, Katja
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Cocks, Kim
    Popa-McKiver, Mihaela
    Chen, Clara
    Cavo, Michele
    BLOOD, 2019, 134
  • [50] Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
    Martin, Thomas G.
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345